Cyclophilin, a primary molecular target for cyclosporine: Structural and functional im plications

Transplantation

Volumn 46, Issue 2, 1988, Pages 29S-35S

  Handschumacher, Robert E ^a   Harding, Matthew W ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHILIN; CYCLOSPORIN A; CYTOSOL RECEPTOR; IMMUNOSUPPRESSIVE AGENT; LYMPHOKINE; RADIOISOTOPE;

BIOLOGICAL MODEL; DRUG PROTEIN BINDING; LYMPHOCYTE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM;

ANIMAL; CARRIER PROTEINS; CATTLE; CELL COMPARTMENTATION; CYCLOSPORINS; CYTOSOL; LYMPHOCYTE ACTIVATION; PEPTIDYLPROLYL ISOMERASE; PROTEIN KINASES; SUPPORT, NON-U.S. GOV'T; T-LYMPHOCYTES; TISSUE DISTRIBUTION;

EID: 0023789280     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Borel JF, Fuerer C, Gubler HU, Stahelin H. Biological effects of cyclosporin A. Agents Actions 1976; 6: 468.
2. Cohen DJ, Leortscher R, Rubin MF, Tilney NL, Carpenter CB, Strom TB. Cyclosporine: a new immunosuppressive agent for organ transplantation. Ann Int Med 1984; 101: 667.
3. Kennedy MS, Deeg HJ, Storb R, et al. Treatment of acute graft versus host disease after allogeneic marrow transplantation: randomized study comparing corticosteroids and cyclosporin. Am J Med 1985; 78: 978.
4. Stiller CR, Dupre J, Gent M, et al. Effect of cyclosporin immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 1984; 223: 1362.
5. Weinblatt ME. Coblyn JS, Fraser PA, et al. Cyclosporin A treatment of refractory rheumatoid arthritis. Arth Rheum 1987; 30: 11.
6. Schmitz-Schumann M. Interim report of clinical studies presented at the international symposium on cyclosporin in autoimmune diseases. Prog Allergy 1986; 38: 436.
7. Nussenblatt RB, Palestine AG, Rook AH, Scher I, Wacker WC, Gery I. Treatment of intraocular inflammatory disease with cyclosporin A. Lancet 1983; 2: 235.
8. Ellis CN, Gorsulowsky DC, Hamilton TA. et al. Cyclosporine improves psoriasis in a double-blind study. JAMA 1986; 256: 3110.
9. Biren CA, Barr RJ. Dermatologie applications of cyclosporine. Arch Dermatol 1986; 122: 1028.
10. Nickell SP, Scheibel LW, Cole GA. Inhibition by cyclosporin A of rodent malaria in vivo and human malaria in vitro. Infect Immunity 1982; 37: 1093.
11. Bueding BE, Hawkins J, Cha YN. Antischistosomal effects of cyclosporin A. Agents Actions 1981; 11: 380.
12. Toterman TH, Danersund A, Nilsson K, Killander A. Cyclosporin A is selectively cytotoxic to human leukemia T cells in vitro. Blood 1982; 59: 1103.
13. Maddox AM, Kahan BD, Tucker S, Kerman R, Jordan RE. Remission in skin infiltrate of a patient with mycosis fungoides treated with cyclosporin A. J Am Acad Dermatol 1985; 12: 952.
14. Solback W, Lange CE, Rollinghoff M, Wagner H. Growth, interleukin 2 production and responsiveness to IL-2 in T4 positive T - lymphocyte population from malignant cutaneous T-cell lymphoma (Sezary syndrome): the effect of cyclosporine A. Blood 1984; 64: 1022.
15. Slater LM, Sweet P, Stupecky M, Gupta S. Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. J Clin Invest 1986; 77: 1405.
16. Hait WN, Stein JM, Koletsky AJ, Slater LM, Harding MW, Handschumacher RE. Modulation of doxorubicin (DOX) resistance by cyclosporin A (CsA) and a non-immunosuppressive homology [Abst 1181]. Proc AARC 1987; 28: 298.
17. Hess AD, Tutschka РJ. Effect of cyclosporin A on human lymphocyte responses in vitro: I. CsA allows for the expression of alloantigen-activated suppressor cells while preferentially inhibiting the inhibition of cytolytic effector lymphocytes in MLR. J Immunol 1980; 124: 2601.
18. Borel JF, Feurer C, Magnee C, Stahelin H. Effects of the new antilymphocytic peptide cyclosporin A in animals. Immunology 1977; 32: 1017.
19. Maraguchi A, Butler JL, Kehrl JH, Falkoff RJ, Fauci AS. Selective suppression of an early step in human B cell activation by cyclosporin A. J Exp Med 1983; 158: 690.
20. Klaus GGB, Hawrylowicz CM. Activation and proliferation signal in mouse B cells: II. Evidence for activation (G0 to Gi) signals differing in sensitivity to cyclosporin. Eur J Immunol 1984; 14: 250.
21. Shevach EM. The effects of cyclosporin A on the immune system. Annu Rev Immunol 1985; 3: 397.
22. Herold KC, Lancki DW, Moldwin RL, Fitch FW. Immunosuppressive effects of cyclosporin A on cloned T cells. J Immunol 1986; 126: 1315.
23. Granelli-Piperno A, Andrus L, Steinman R. Lymphokine and nonlymphokine mRNA in stimulated human T cells: kinetics, mitogen requirements and effects of cyclosporin A. J Exp Med 1984; 160: 1792.
24. Kronke M, Leonard WJ, Depper JM, et al. Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription. Proc Natl Acad Sei USA 1984; 81: 5214.
25. Elliot JF, Lin Y, Mizel SB, Bleackley RC, Harnish DG, Paetkav V. Induction of interleukin 2 messenger RNA inhibited by cyclosporine A. Science 1984; 226: 1439.
26. Reed JC, Alpers JD, Nowell PC, Hoover RG. Sequential expression of protooncogenes during lectin-stimulated mitogenesis of normal human lymphocytes. Proc Natl Acad Sei USA 1986; 83: 3982.
27. Handschumacher RE, Harding MW, Rice J, Drugge RJ, Speicher DW. Cyclophilin: A specific cytosolic binding protein for cyclosporine A. Science 1984; 226: 544.
28. Harding MW, Handschumacher RE, Speicher DW. Isolation and amino acid sequence of cyclophilin. J Biol Chem 1986; 261: 8547.
29. Laemmli UK. Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature 1970; 227: 680.
30. Hunter T, Sefton BM. Transforming gene product of rous sarcoma virus phosphorylates tyrosine. Proc Natl Acad Sei USA 1980; 77: 1311.
31. Merker MM, Handschumacher RE. Uptake and nature of the intracellular binding of cyclosporin A in a murine thymoma cell line, BW5147. J Immunol 1983; 132: 3064.
32. Ryffel B, Gotz U, Heuberger B. Cyclosporin receptors on human lymphocytes. J Immunol 1982; 129: 1978.
33. Ryffel B, Donatsch Ρ, Gotz U, Tschopp M. Cyclosporin receptor on mouse lymphocytes. Immunology 1980; 41: 913.
34. LeGrue SJ, Friedman AW, Kahan BD. Binding of cyclosporin by human lymphocytes and phospholipid vesicles. J Immunol 1983;
35. Quesniaux VFJ, Schreier ΜΗ, Wenger RM, Hiestand PC, Harding MW, Van Regenmortei MHV. Cyclophilin binds to the region of cyclosporine involved in its immunosuppressive activity. Eur J Immunol 1987; 17: 1359.
36. Quesniaux VFJ, Schreier ΜΗ, Wenger RM, Hiestand PC, Harding MW, Van Regenmortel MHV. Molecular characteristics of cyclophilin- cyclosporine interaction. Transplantation (in press).
37. Haendler B, Hofer Warbinek, Hofer E. Complementary DNA for human T-cell cyclophilin. EMBO J 1987; 6: 947.
38. Dalgarno DC, Harding MW, Lazarides AA, Handschumacher RE, Armitage IM. ’HNMR studies on bovine cyclophilin: preliminary structural characterization of this specific cyclosporin A binding protein. Biochemistry 1986; 25: 6778.
39. Merker M, Rice J, Schweitzer B, Handschumacher RE. Cyclosporin A binding component in BW5147 lymphoblasts and normal lymphoid tissues. Transplant Proc 1983; 15: 2265.
40. Koletsky AJ, Harding MW, Handschumacher RE, Cyclophilin: distribution and variant properties in normal and neoplastic tissues. J Immunol 1086; 137: 1054.
41. Saydjari R, Townsend CM, Barranco SC. Effects of cyclosporine and α-difluoromethylornithine on the growth of mouse colon cancer in vitro. Life Sei 1987; 40: 359.
42. Hannink M, Donoghue DJ. Lysine residue 121 in the proposed ATP-binding site of the v-mos protein is required for transformation. Proc Natl Acad Sei USA 1985; 82: 7894.
43. Walker JE, Saraste M, Runswick MJ, Gay NJ, Distantly related sequences in the a and /З-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold. EMBO J 1982; 1: 945.
44. Harding MW, Gorelick FS, Handschumachei RE. Cyclophilin represents a novel class of protein kinases. [Abst 1377], Fed Proc 1987; 46: 2161.
45. Nairn AC, Hemmings HC, Greengard P. Protein kinases in the brain. Annu Rev Biochem 1985; 54: 931.
46. Hidaka H, Inagaki M, Kawamoto S, Sasaki Y. Isoquinoline sulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry 1984; 23: 5036.
47. Housey GM, O’Brian CA, Johnson MD, Kirschmeier P, Weinstein IB. Isolation of cDNA clones encoding protein kinase C: evidence for a protein kinase C-related gene family. Proc Natl Acad Sei USA 1987; 84: 1065.
48. Jaken S, Kiley SC. Purification and characterization of three types of protein kinase C from rabbit brain cytosol. Proc Natl Acad Sei USA 1987; 84: 4418.
49. Jahnsen T, Hedin L, Kidd VJ, et al. Molecular cloning, cDNA structure and regulation of the regulatory subunit of type II cAMP-dependent protein kinase from rat ovarian granuloma cells. J Biol Chem 1986; 261: 12352.
50. Coossens L, Parker PJ, Rhee L, et al. Multiple, distinct forms of bovine and human protein kinase C suggest diversity in cellular signaling pathways. Science 1986; 233: 859.
51. Metcalf S. Cyclosporine does not prevent cytoplasmic calcium changes associated with lymphocyte activation. Transplantation 1984; 38: 161.
52. Wiskocil R, Weiss A, Imboden J, Kamin-Lewis R, Stobo J. Activation of a human T cell line: a two stimulus requirement in the pretranslational events involved in the coordinate expression of interleukin 2 and α-interferon genes. J Immunol 1985; 134: 1599.
53. Gelfand EW, Cheung R, Mills GB. The cyclosporins inhibit lymphocyte activation at more than one site. J Immunol 1987; 138: 1115.
54. Nobrega AF, Maldonado MS, Dos Reis GA. Analysis of isolated and combined effects of calcium ionophore and phorbol ester on T lymphocyte activation. Clin Exp Immunol 1986; 65: 559.
55. Edwards MC, Nouri AME, Gordon D, Evans FJ. Tumor promoting and nonpromoting pro-inflammatory esters act as human lym cyclosporin A. Mol Pharmacol 1983; 23: 703.
56. Manger B, Hardy KJ, Weiss A, Stobo JD. Differential effect of cyclosporin A on activation signaling in human T cell lines. J Clin Invest 1986; 77: 1501.
57. Rosoff PM, Terres G. Cyclosporine A inhibits Ca++ dependent stimulation of the Na+/H + antiport in human T cells. J Cell Biol 1986; 103: 457.
58. Szamel M, Berger P, Resch K. Inhibition of T lymphocyte activation by cyclosporin A: interference with the early activation of plasma membrane phospholipid metabolism. J Immunol 1986; 136: 264.
59. Colambani PM, Robb A, Hess AD. Cyclosporin A binding to calmodulin: a possible site of action on T lymphocytes. Science 1985; 228: 337.
60. Colambani PM, Robb A, Hess AD. Cyclosporin A binding to calmodulin: a possible site of action on T lymphocytes. Science 1985; 228: 337.
61. Hess AD, Colombani PM. Mechanism of action of cyclosporine: role of calmodulin, cyclophilin and other cyclosporine-binding proteins. Transplant Proc 1986; 18: 219.
62. Foxwell BMJ, Hiestand PC, Wenger RM, Ryffel B. A comparison of cyclosporine-binding by cyclophilin and calmodulin and the identification of a novel 45 kd binding phosphoprotein. Transplantation (in press).